dc.contributor.author | Ueland, Thor | |
dc.contributor.author | Kleveland, Ola | |
dc.contributor.author | Michelsen, Annika | |
dc.contributor.author | Wiseth, Rune | |
dc.contributor.author | Damås, Jan Kristian | |
dc.contributor.author | Aukrust, Pål | |
dc.contributor.author | Gullestad, Lars | |
dc.contributor.author | Halvorsen, Bente | |
dc.contributor.author | Yndestad, Arne | |
dc.date.accessioned | 2019-02-28T12:31:28Z | |
dc.date.available | 2019-02-28T12:31:28Z | |
dc.date.created | 2018-12-08T11:13:17Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Open heart. 2018, 5:000765 (2), 1-7. | nb_NO |
dc.identifier.issn | 2053-3624 | |
dc.identifier.uri | http://hdl.handle.net/11250/2588054 | |
dc.description.abstract | Objective It is unclear if activation of inflammatory pathways regulates proprotein convertase subtilisin-kexin type 9 (PCSK9) levels.
Approach We evaluated (1) the temporal course of serum PCSK9 during hospitalisation following acute coronary syndrome and associations with markers of inflammation (leucocyte counts, interleukin (IL)-6, C-reactive protein) and lipid levels and (2) the effect of inhibition of IL-6 signalling with the IL-6 receptor antibody tocilizumab on PCSK9 levels in a randomised, double-blind, placebo-controlled trial release in patients with non-ST-elevation myocardial infarction.
Results Serum PCSK9 increased during the acute phase and this response was modestly associated with neutrophil counts (r=0.24, p=0.009) and presence of hypercholesterolaemia (r=0.019, p=0.045), but was not modified by tocilizumab. However, a modifying effect of tocilizumab on PCSK9 levels was observed in patients with hypercholesterolaemia (p=0.024, repeated measures analysis of variance) and this effect was strongly correlated with the decrease in neutrophils (r=0.66, p=0.004).
Conclusions Our study suggests that patients with a more atherogenic profile may benefit from anti-IL-6 therapy with regard to PCSK9. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | BMJ Publishing Group | nb_NO |
dc.rights | Navngivelse-Ikkekommersiell 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/deed.no | * |
dc.title | Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.description.version | publishedVersion | nb_NO |
dc.source.pagenumber | 1-7 | nb_NO |
dc.source.volume | 5:000765 | nb_NO |
dc.source.journal | Open heart | nb_NO |
dc.source.issue | 2 | nb_NO |
dc.identifier.doi | 10.1136/openhrt-2017-000765 | |
dc.identifier.cristin | 1640591 | |
dc.description.localcode | © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | nb_NO |
cristin.unitcode | 194,65,25,0 | |
cristin.unitcode | 194,65,15,0 | |
cristin.unitname | Institutt for sirkulasjon og bildediagnostikk | |
cristin.unitname | Institutt for klinisk og molekylær medisin | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |